Daniel Schneeberger-led Adar1 Capital purchases 2.18 million USD worth of Rallybio stock in a recent filing.
Adar1 Capital, led by portfolio manager Daniel Schneeberger, has acquired $2.18 million in Rallybio Corporation shares. The purchase was disclosed in a recent regulatory filing, reflecting a strategic investment in the biopharmaceutical firm.
Rallybio, focused on rare disease therapies, has seen fluctuating stock performance amid clinical trial updates and partnerships. The acquisition follows a period of modest trading volume for Rallybio shares, which closed at $12.50 in the prior session.
No immediate market reaction was reported following the disclosure.